Anavex Life Sciences Corp (AVXL)

[falconer66a]

Well, then, tell the experiments.

These are experimental drugs....

Oh, really? That’s one from the Anavex naysayers I missed. “Blarcamesine can’t be a real drug. It’s just experimental.”

Fine. Now, tell us what is being experimented with? One does experiments to discover something. What, presently, is being experimented with in regard to blarcamesine? Collecting clinical data is not by any means an experiment; it’s an effort to confirm preclinical (truly experimental) data.

No, blarcamesine is in no way “experimental.” An abundance of “experiments” have already been conducted on the drug, first in murines (lab rodents), then in increasingly larger early-stage human clinical trials. Those have been all positive. Now, they need to be confirmed (not experimented with) by proper clinical trials. Those are in progress. When enlisting patients to participate in those trials did Anavex say, “Please allow us to experiment with our drug, inside your diseased body?”

Biogen’s Adulhelm got FDA approval. In that case, when did experimentation end and the drug attain “non-experimental” status? Are FDA clinical trials ever allowed to be used for “experimentation?” Of course not. For Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s disease, there is no experimentation with blarcamesine. Things have moved on to the next step, to prove in large, properly-configured human trials both safety and efficacy. Anavex (and the FDA) are no longer experimenting with blarcamesine. Experimentation is all preclinical. Done.

Blarcamesine is not experimental in any respect. It’s a well-researched (experimented-with) drug now in the clinical trials required for sales and use approval by the FDA. FDA doesn’t allow experimentation on humans during clinical trials. Just the opposite. All factors have to be held constant, so that the safety and efficacies of the particular drug can be accurately determined. No experimentation allowed.